Efficacy And Safety of Intravenous FCM and Iron Sucrose (IS) in Post-partum Iron-Deficiency Anaemia: A Comparative Study
Authors/Creators
- 1. Senior Resident, Department of Obstetrics and Gynaecology, Netaji Subhas Medical College and Hospital, Bihta, Patna, Bihar, India
- 2. Tutor, Department of Pharmacology, Darbhanga Medical College and Hospital, Laheriasarai, Darbhanga, Bihar, India
Description
Aim: A comparative study of efficacy, safety and compliance of intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnancy. Methods: This comparative study was carried out in the Department of Obstetrics and Gynaecology, Netaji Subhas Medical College and Hospital, Bihta, Patna, Bihar, India. Women less than 10 days after delivery with hemoglobin between ≥6 g/dl and ≤11 gm/dl requiring iron supplementation were enrolled. Total 200 women were categorized into two groups 100 each. Detailed history and clinical examination were done. Diagnosis was confirmed by peripheral blood smear, CBC and serum ferritin. All women were dewormed. Results: Mean pre-treatment Hb was 8.1±0.77 and 8.11±0.61 in iron sucrose and ferric carboxy maltose group respectively. There was statistically significant rise (P <0.001) of Hb in FCM group 4.88 g/dl compared to iron sucrose group 3.82 g/dl. Mean rise of serum ferritin was 72.07±26.23 and 96.39±44.84 in iron sucrose and ferric carboxy maltose group. No serious adverse events were reported in either the FCM group or iron sucrose group. However, minor adverse effects like urticaria, injection site reactions, nausea hypotension occurred in 7 (7%) iron sucrose group and chest discomfort was noted in 2, nausea in 1, (3%) of FCM group. Conclusion: Properties like ultra-short duration of treatment, fewer adverse reactions and better compliance makes FCM the first-line drug in the management of postpartum iron deficiency anemia.
Abstract (English)
Aim: A comparative study of efficacy, safety and compliance of intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnancy. Methods: This comparative study was carried out in the Department of Obstetrics and Gynaecology, Netaji Subhas Medical College and Hospital, Bihta, Patna, Bihar, India. Women less than 10 days after delivery with hemoglobin between ≥6 g/dl and ≤11 gm/dl requiring iron supplementation were enrolled. Total 200 women were categorized into two groups 100 each. Detailed history and clinical examination were done. Diagnosis was confirmed by peripheral blood smear, CBC and serum ferritin. All women were dewormed. Results: Mean pre-treatment Hb was 8.1±0.77 and 8.11±0.61 in iron sucrose and ferric carboxy maltose group respectively. There was statistically significant rise (P <0.001) of Hb in FCM group 4.88 g/dl compared to iron sucrose group 3.82 g/dl. Mean rise of serum ferritin was 72.07±26.23 and 96.39±44.84 in iron sucrose and ferric carboxy maltose group. No serious adverse events were reported in either the FCM group or iron sucrose group. However, minor adverse effects like urticaria, injection site reactions, nausea hypotension occurred in 7 (7%) iron sucrose group and chest discomfort was noted in 2, nausea in 1, (3%) of FCM group. Conclusion: Properties like ultra-short duration of treatment, fewer adverse reactions and better compliance makes FCM the first-line drug in the management of postpartum iron deficiency anemia.
Files
IJPCR,Vol14,Issue1,Article115.pdf
Files
(147.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:1cee3d4d044fb3efad4f61f0b7b71d55
|
147.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-01-23
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue1,Article115.pdf
- Development Status
- Active
References
- 1. World Health Organization. Iron Deficiency Anemia Assessment Prevention and Control: A Guide for Program Managers. Geneva Switzerland; World Health Organization; 2001. 2. Reveiz L, Gyte GM, Cuervo LG. Treatments for iron- deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2007;2:CD003094. 3. World Health Organization. The Prevalence of Anaemia in Women: A Tabulation of Available Information (WHO/MCH/MSM/92) WHO, Maternal Health and Safe Motherhood Programme. Geneva, Switzerland: Division of Family Health; 1992. 4. Kalaivani K. Prevalence and consequences of anaemia in pregnancy. Indian J Med. 2009;130:627–33. 5. Ezzati M, Lopus AD, Dogers A, Vander HS, Murray C. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-60. 6. IIPS National Family Health Survey 1998-99 (NFHS-2); 2013. Available from: http://www.nfhsindia.org/india2.html. 7. IIPS. National Family Health Survey 2005-06 (NFHS-3). Available from: http://mohfw.nic.in/nfhsfactsheet.htm. 8. DLHS on RCH. Nutritional status of children and prevalence of anaemia among children, adolescent grils and pregnant women 2002- 2004; 2006. Available from: http://www.rchindia.org/nr_india.htm. 9. Toteja GS, Singh P. Micronutrient status of Indian population. Indian J Med Res. 2018;148(5):511–21. 10. National Nutrition Monitoring Bureau (NNMB). NNMB Micronutrient survey. Hyderabad: National Institute of Nutrition; 2002. 11. Sanoussi M, N. ., Brahim, B. ., Derkaoui, A. ., Abdelkrim, S. ., & Mohammed, K. . (2022). Risk factors for sepsis in severe head trauma. Journal of Medical Research and Health Sciences , 5 (1), 1653– 1657. https://doi.org/10.52845/JMRHS/2022/5-1-3 12. Mcmahon LP. Iron deficiency in pregnancy. Obstet Med. 2010;3:17– 24. 13. Mitman N. Prepartum anaemia: prevention and treatment. Ann Hematol. 2008;87:949-59. 14. Malek A. In vitro studies of ferric carboxymaltose on placental permeability using the dual perfusion model of human placenta. Arzneimittelforschung. 2010;60(6a):354-61. 15. Pfenniger A, Schuller C, Christoph P, Surbek D. Safety and efficacy of highdose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia. J Perinat Med. 2012;40(4):397-402. 16. Breymann C. The use of iron sucrose complex for anemia in pregnancy and postpartum period. Semin Hematol. 2006;43(6):28-31. 17. Seid MH, Mangione A, Valaoras TG, Anthony LB, Barish CF. Safety Profile of Iron Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Blood. 2006;108:3739 18. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101(1):67-73 19. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435-7. 20. Khandale SN, Kedar K. Managing postpartum anemia with ferric carboxymaltose at tertiary level hospital: a retrospective study. J Evolution Med Dental Sci. 2015;4(44):7580-6. 21. Verma U, Singh S, Chandra M, Garg R, Singh S. To evaluate the efficacy and safety of single dose intravenous iron carboxymaltose verses multidose iron sucrose in post-partum cases of severe iron deficiency anemia. Int J Reprod Contracept Obstet Gynecol. 2015;4(2):442-6.